Skip to main content

Ocean Biomedical (NASDAQ: OCEA) Receives U.S. Patent Approval Notice for New Malaria Treatment

Ocean Biomedical, Inc. (NASDAQ: OCEA) is engaged as a biopharmaceutical company, which is focused on the development and commercialization of innovative treatments for life-threatening diseases. Shares of the biopharma company are soaring 46% through early trading on Thursday, April 13, 2023. Over the past three months, Ocean Biomedical has seen average daily volume of 2.14 million shares. However, volume of 13.1 million shares or dollar volume of around $87.64 million, has already exchanged hands through early trading.

Shares of Ocean Biomedical are climbing after the company announced that its co-founder and member of the board of directors, Dr. Jonathan Kurtis, MD, has received a Notice of Allowance from the U.S. Patent and Trademark Office (USPTO) for a patent application on a new therapeutic and prophylactic monoclonal antibody that is capable of killing falciparum malaria parasites. Ocean Biomedical says they anticipate the patent to be officially issued in the coming months.

The news comes as Dr. Kurtis and Ocean Biomedical build upon a monumental discovery that PfGARP is a potential effective vaccine target to treat malaria. Dr. Kurtis was then able to discover and produce a monoclonal antibody that is capable of binding to PfGARP and ultimately triggers the malaria parasite to kill itself.

Dr. Kurtis and his team will now work on further developing the monoclonal antibody as a potential therapeutic drug for severe malaria infection, as well as for individuals living in regions that are known for short malaria transmission seasons.

“Inducing parasite cell death via targeting PfGARP is a novel approach that has potential to launch a whole new class of anti-malarials, including mRNA-based vaccines, small molecules and the current monoclonal antibody,” said Dr. Kurtis. “Our monoclonal comes at a critical time because malaria parasites are developing resistance to current frontline therapeutics, and because the currently approved vaccine offers only very limited protection.”

Disclosure: No position. Spotlight Growth has no relationships with any of the companies mentioned in this article and did not receive payment in any form for its creation. This is an opinion article and is not meant to be financial advise. We are not broker-dealers or investment professionals. Please conduct your own due diligence. For more information on our disclosures, please visit:

The post Ocean Biomedical (NASDAQ: OCEA) Receives U.S. Patent Approval Notice for New Malaria Treatment appeared first on Spotlight Growth.

Data & News supplied by
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.